Acorda Therapeutics, Inc. Profile Avatar - Palmy Investing

Acorda Therapeutics, Inc.

Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis…

Drug Manufacturers - Specialty & Generic
US, Ardsley [HQ]
Revenue Breakdowns

Segment Analysis Beta

The financial segments are sourced from the SEC' 10-K statement.

Revenue By Top Segments

Acorda Therapeutics, Inc. can't present it's sankey chart.

Historical Revenue By Segment

Last 3Y, in million USD

Acorda Therapeutics, Inc. can't present revenue by segment

Get PRO Today

With PRO you can bypass the blur for the segment revenues of Acorda Therapeutics, Inc..

If you want to see a demo, head over to the financial segments of AAPL

End of ACOR's Analysis
CIK: 1008848 CUSIP: 00484M106 ISIN: US00484M7002 LEI: - UEI: -
Secondary Listings
ACOR has no secondary listings inside our databases.